Tango Therapeutics logo
TNGXTango Therapeutics
Trade TNGX now
Tango Therapeutics primary media

About Tango Therapeutics

Tango Therapeutics (NASDAQ:TNGX) focuses on discovering and delivering transformative cancer therapies. With a commitment to leveraging the latest in scientific research to address unmet needs in oncology, Tango is dedicated to identifying and exploiting cancer vulnerabilities through a precision medicine approach. Their projects revolve around developing a diverse pipeline of innovative treatment options that aim to improve outcomes for patients with various cancer types. Operating at the intersection of groundbreaking science and patient-centric development, Tango's objectives include advancing these projects through clinical trials, securing regulatory approvals, and ultimately making these therapies available to the patients who need them the most.

What is TNGX known for?

Snapshot

Public US
Ownership
2017
Year founded
160
Employees
Massachusetts, United States
Head office
1 of 5
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
United States

Products and/or services of Tango Therapeutics

  • Development of targeted cancer therapies using CRISPR-based functional genomics to identify novel drug targets.
  • Advancement of a personalized cancer vaccine platform for various tumor types.
  • Research on small molecule inhibitors targeting synthetic lethal interactions in cancer cells.
  • Creation of a suite of bioinformatics tools for the analysis of cancer genomics data.
  • Efforts in molecular diagnostics for early cancer detection and treatment decision support.
  • Collaboration with pharmaceutical companies to co-develop and bring targeted cancer therapies to market.

Tango Therapeutics executive team

  • Dr. Barbara L. Weber M.D.Founder & Executive Chair
  • Dr. Malte Peters M.D.President, CEO & Director
  • Ms. Daniella Beckman CPAChief Financial Officer
  • Mr. Douglas J. Barry Esq., J.D.Chief Compliance Officer & Corporate Secretary
  • Dr. Adam S. Crystal M.D., Ph.D.President of Research & Development
  • Prof. Alan Ashworth FRS, Ph.D.Founder & Member of Scientific Advisory Board
  • Dr. William G. Kaelin Jr., M.D.Founder & Member of Scientific Advisory Board
  • Dr. Antoni Ribas M.D., Ph.D.Founder & Member of Scientific Advisory Board
  • Dr. Michael Palmieri Ph.D.Chief Technical Operations Officer
  • Mr. Jannik N. Andersen Ph.D.Chief Scientific Officer

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.